[go: up one dir, main page]

MX2024010655A - Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. - Google Patents

Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.

Info

Publication number
MX2024010655A
MX2024010655A MX2024010655A MX2024010655A MX2024010655A MX 2024010655 A MX2024010655 A MX 2024010655A MX 2024010655 A MX2024010655 A MX 2024010655A MX 2024010655 A MX2024010655 A MX 2024010655A MX 2024010655 A MX2024010655 A MX 2024010655A
Authority
MX
Mexico
Prior art keywords
disease
treat alzheimer
riluzole
riluzole prodrugs
prodrugs
Prior art date
Application number
MX2024010655A
Other languages
English (en)
Inventor
Vladimir Coric
Robert Berman
Irfan Qureshi
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of MX2024010655A publication Critical patent/MX2024010655A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen métodos para tratar la enfermedad de Alzheimer al administrar a un paciente en necesidad de esto un profármaco de riluzol tal como troriluzol. También se describen composiciones farmacéuticas y kits que incluyen profármacos de riluzol.
MX2024010655A 2018-07-22 2021-01-14 Uso de profarmacos de riluzol para tratar enfermedad de alzheimer. MX2024010655A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22

Publications (1)

Publication Number Publication Date
MX2024010655A true MX2024010655A (es) 2024-09-11

Family

ID=69181140

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000515A MX2021000515A (es) 2018-07-22 2019-07-20 Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
MX2024010655A MX2024010655A (es) 2018-07-22 2021-01-14 Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021000515A MX2021000515A (es) 2018-07-22 2019-07-20 Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.

Country Status (14)

Country Link
US (1) US12161633B2 (es)
EP (1) EP3823616A4 (es)
JP (2) JP2021530543A (es)
KR (1) KR20210034621A (es)
CN (1) CN112469408A (es)
AU (1) AU2019310013B2 (es)
BR (1) BR112021000768A2 (es)
CA (1) CA3107215A1 (es)
EA (1) EA202190308A1 (es)
IL (1) IL280177B2 (es)
MX (2) MX2021000515A (es)
PH (1) PH12021550043A1 (es)
SG (1) SG11202100385YA (es)
WO (1) WO2020023324A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3187323A1 (en) * 2020-06-24 2021-12-30 Biohaven Therapeutics Ltd. Compositions and methods for treating obsessive-compulsive disorder
WO2022076321A1 (en) * 2020-10-05 2022-04-14 Icahn School Of Medicine At Mount Sinai Riluzole for the treatment of alzheimer's disease
US20240082340A1 (en) * 2021-01-18 2024-03-14 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
US20240148885A1 (en) * 2021-02-22 2024-05-09 Yale University Targeted bifunctional degraders
CN114344297B (zh) * 2022-03-01 2024-05-14 暨南大学 利鲁唑在治疗少精症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7552501A (en) * 2000-06-14 2002-01-08 Corixa Corp Tripeptide prodrug compounds
KR101358078B1 (ko) * 2004-11-01 2014-02-06 주식회사 유스팜인터내셔널 근위축성 측삭 경화증의 신경퇴행을 감소시키기 위한 방법및 조성물
FR2957077B1 (fr) 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
CA2933464A1 (en) 2013-12-09 2015-06-18 Thomas Jefferson University Use of abc drug efflux inhibitors in combination with anti-neurodegenerative drugs in the treatment of neurodegenerative disorders
CA2967826C (en) * 2014-11-26 2024-01-16 Medicinova, Inc. A combination of ibudilast and riluzole and methods of using same
KR102587894B1 (ko) * 2015-03-03 2023-10-12 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 릴루졸 전구약물 및 그의 용도
CA3025019A1 (en) * 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
US12029731B2 (en) 2016-08-10 2024-07-09 Biohaven Therapeutics Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
JP7354123B2 (ja) * 2018-02-21 2023-10-02 エイアイ・セラピューティクス・インコーポレーテッド アピリモドとグルタミン酸作動薬を用いた併用療法
US20240082340A1 (en) * 2021-01-18 2024-03-14 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease

Also Published As

Publication number Publication date
CN112469408A (zh) 2021-03-09
SG11202100385YA (en) 2021-02-25
WO2020023324A1 (en) 2020-01-30
MX2021000515A (es) 2021-06-08
PH12021550043A1 (en) 2021-09-20
EP3823616A4 (en) 2022-05-04
AU2019310013B2 (en) 2025-01-02
JP2025093952A (ja) 2025-06-24
US12161633B2 (en) 2024-12-10
IL280177B1 (en) 2024-09-01
IL280177A (en) 2021-03-01
IL280177B2 (en) 2025-01-01
CA3107215A1 (en) 2020-01-30
EP3823616A1 (en) 2021-05-26
KR20210034621A (ko) 2021-03-30
EA202190308A1 (ru) 2021-05-19
BR112021000768A2 (pt) 2021-05-11
JP2021530543A (ja) 2021-11-11
AU2019310013A1 (en) 2021-02-11
US20210290599A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
MX2024010655A (es) Uso de profarmacos de riluzol para tratar enfermedad de alzheimer.
ZA202204929B (en) Rimegepant for cgrp related disorders
PH12018502634A1 (en) Topical compositions of apremilast
ZA202002626B (en) Use of riluzole prodrugs to treat ataxias
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12021550443A1 (en) Pyridazinones and methods of use thereof
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
JOP20190191A1 (ar) وحدات شجرية علاجية
MX2020002884A (es) Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
MY207469A (en) Therapeutic compounds
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12021550671A1 (en) Prodrugs of cgrp antagonists
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
MX2016008968A (es) Compuestos organicos.
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
MX2019003720A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202091162A1 (ru) Применение пролекарств рилузола для лечения атаксии